Neural Regeneration Research ›› 2020, Vol. 15 ›› Issue (3): 448-449.doi: 10.4103/1673-5374.266057

Previous Articles     Next Articles

Administration of pre/probiotics with conventional drug treatment in Alzheimer’s disease.

Jakub Hort1,2, Martin Valis3, Francesco Angelucci1   

  1. 1Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic  2International Clinical Research Centre, St. Anne’s University Hospital, Brno, Czech Republic  3Department of Neurology, University Hospital Hradec Králové, Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic 
  • Online:2020-03-15 Published:2020-05-26
  • Contact: Francesco Angelucci, PhD,francesco.angelucci@lfmotol.cuni.cz.
  • Supported by:
    This work was supported by the Project No. LQ1605 from the National Program of Sustainability II (MEYS CR), the European Regional Development Fund-Project ENOCH (CZ.02.1.01/0.0/0.0/16_019/0000868), the Institutional Support of Excellence 2. LF UK (699012) and by the Grant Agency of Charles University (Project no. 176317); partially supported by the grants from the Ministry of Education, Youth and Sports of the Czech Republic (PROGRES Q40) and from the Ministry of Health of the Czech Republic (RVO–FN HK 00179906); supported by the project IT4Neuro(- degeneration), reg. nr. CZ.02.1.01/0.0/0.0/18_069/0010054.

PDF

229

Abstract: Alzheimer’s disease (AD) is a neurodegenerative disease with long preclinical phase, typically followed by a slow decline in memory, thinking and reasoning abilities. The underlying pathological processes are not yet fully elucidated, although two main disease hallmarks have been associated with AD pathology: amyloid beta species and neurofibrillary tangles. The plaques are deposits of a protein fragment called beta-amyloid (Aβ), which accumulates in the spaces between neurons. Tangles are twisted fibers of the tau protein, which accumulates inside the cells.